The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•23 March 2026•

1 min read

Futura Medical Reports Positive Trial Results for Upgraded Eroxon Intense Gel

Key Facts

1Futura Medical reported positive home user trial results for its new Eroxon Intense formulation.

2The study involved 223 participants and showed high efficacy rates for mild to moderate erectile dysfunction.

Futura Medical PLC has announced successful results from a four-week home user trial for its new Eroxon Intense formulation, designed to treat erectile dysfunction. The study, which involved 223 participants, demonstrated high efficacy rates in effectively managing mild to moderate cases. According to the clinical data, the upgraded formula showed significantly stronger early effects compared to the company's existing product currently on the market. These positive outcomes are expected to bolster the company's consumer healthcare portfolio and strengthen its competitive global position. As a key product milestone, these results serve as a bullish catalyst for the company's stock performance on the AIM market. Futura Medical aims to provide faster and more effective solutions for users through this innovation, further validating its long-term growth strategy.